Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On September 7, 2007, there was an increase in the notional allocation of Ordinary Share ADRs at a price of $53.07 per ADR share for Mrs. C Bruck Slaoui.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- The transaction involves an increase in notional ADR allocation for Mrs. C Bruck Slaoui.
- The transaction price was $53.07 per ADR share on September 7, 2007.
- The filing was signed by Simon Bicknell, Company Secretary, on September 12, 2007.
- No financial performance data is included in this specific report.